Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Top biological products, (no diagnostic substances) companies in Delaware, ranked by financial performance.
Delaware Sector Intelligence · Sprytne.com
In Delaware, the biological products, (no diagnostic substances) sector is led by AMGEN INC (AMGN) with $36.75B in annual revenue. The fastest-growing player is 4D Molecular Therapeutics, Inc. at +230194.6% YoY growth.
Based on the latest SEC EDGAR 10-K annual filings · Verified public data
| Rank | Company | Revenue | Details |
|---|---|---|---|
| #1 | AMGEN INCAMGN | $36.75B | YoY: +10.0% |
| #2 | GILEAD SCIENCES, INC.GILD | $29.44B | YoY: +2.4% |
| #3 | BIOGEN INC.BIIB | $9.89B | YoY: +2.2% |
| #4 | NEUROCRINE BIOSCIENCES INCNBIX | $2.86B | YoY: +21.4% |
| #5 | EXELIXIS, INC.EXEL | $2.32B | YoY: +7.0% |
| #6 | Moderna, Inc.MRNA | $1.94B | YoY: -39.9% |
| #7 | HALOZYME THERAPEUTICS, INC.HALO | $1.40B | YoY: +37.6% |
| #8 | NOVAVAX INCNVAX | $1.12B | YoY: +64.7% |
| #9 | BIOCRYST PHARMACEUTICALS INCBCRX | $874.8M | YoY: +94.1% |
| #10 | REPLIGEN CORPRGEN | $738.3M | YoY: +16.4% |
| #11 | ADMA BIOLOGICS, INC.ADMA | $510.2M | YoY: +19.6% |
| #12 | Tarsus Pharmaceuticals, Inc.TARS | $451.4M | YoY: +146.7% |
| #13 | Twist Bioscience CorpTWST | $376.6M | YoY: +20.3% |
| #14 | IOVANCE BIOTHERAPEUTICS, INC.IOVA | $263.5M | YoY: +60.6% |
| #15 | Ginkgo Bioworks Holdings, Inc.DNA | $170.2M | YoY: -25.1% |
| #16 | Maze Therapeutics, Inc.MAZE | $167.5M | — |
| #17 | Beam Therapeutics Inc.BEAM | $139.7M | YoY: +120.0% |
| #18 | Monte Rosa Therapeutics, Inc.GLUE | $123.7M | YoY: +63.5% |
| #19 | Atara Biotherapeutics, Inc.ATRA | $120.8M | YoY: -6.3% |
| #20 | AGENUS INCAGEN | $114.2M | YoY: +10.4% |
| #21 | ImmunityBio, Inc.IBRX | $113.3M | YoY: +668.3% |
| #22 | Century Therapeutics, Inc.IPSC | $109.2M | YoY: +1556.8% |
| #23 | 4D Molecular Therapeutics, Inc.FDMT | $85.2M | YoY: +230194.6% |
| #24 | RECURSION PHARMACEUTICALS, INC.RXRX | $74.7M | YoY: +26.9% |
| #25 | Vir Biotechnology, Inc.VIR | $68.6M | YoY: -7.6% |
| Rank | Company | YoY Growth | Details |
|---|---|---|---|
| #1 | 4D Molecular Therapeutics, Inc.FDMT | +230194.6% | Revenue: $85.2M |
| #2 | Century Therapeutics, Inc.IPSC | +1556.8% | Revenue: $109.2M |
| #3 | X4 Pharmaceuticals, IncXFOR | +1273.2% | Revenue: $35.1M |
| #4 | ImmunityBio, Inc.IBRX | +668.3% | Revenue: $113.3M |
| #5 | TScan Therapeutics, Inc.TCRX | +266.7% | Revenue: $10.3M |
| #6 | Tarsus Pharmaceuticals, Inc.TARS | +146.7% | Revenue: $451.4M |
| #7 | Beam Therapeutics Inc.BEAM | +120.0% | Revenue: $139.7M |
| #8 | Invivyd, Inc.IVVD | +110.5% | Revenue: $53.4M |
| #9 | BIOCRYST PHARMACEUTICALS INCBCRX | +94.1% | Revenue: $874.8M |
| #10 | NOVAVAX INCNVAX | +64.7% | Revenue: $1.12B |
| #11 | Monte Rosa Therapeutics, Inc.GLUE | +63.5% | Revenue: $123.7M |
| #12 | IOVANCE BIOTHERAPEUTICS, INC.IOVA | +60.6% | Revenue: $263.5M |
| #13 | Relay Therapeutics, Inc.RLAY | +53.4% | Revenue: $15.4M |
| #14 | HALOZYME THERAPEUTICS, INC.HALO | +37.6% | Revenue: $1.40B |
| #15 | RECURSION PHARMACEUTICALS, INC.RXRX | +26.9% | Revenue: $74.7M |
| #16 | Editas Medicine, Inc.EDIT | +25.4% | Revenue: $40.5M |
| #17 | NEUROCRINE BIOSCIENCES INCNBIX | +21.4% | Revenue: $2.86B |
| #18 | Scilex Holding CoSCLX | +21.1% | Revenue: $56.6M |
| #19 | Twist Bioscience CorpTWST | +20.3% | Revenue: $376.6M |
| #20 | ADMA BIOLOGICS, INC.ADMA | +19.6% | Revenue: $510.2M |
| #21 | REPLIGEN CORPRGEN | +16.4% | Revenue: $738.3M |
| #22 | CHAMPIONS ONCOLOGY, INC.CSBR | +13.5% | Revenue: $56.9M |
| #23 | Caribou Biosciences, Inc.CRBU | +11.7% | Revenue: $11.2M |
| #24 | AGENUS INCAGEN | +10.4% | Revenue: $114.2M |
| #25 | AMGEN INCAMGN | +10.0% | Revenue: $36.75B |
| Rank | Company | Net Income | Details |
|---|---|---|---|
| #1 | GILEAD SCIENCES, INC.GILD | $8.51B | Margin: 28.9% |
| #2 | AMGEN INCAMGN | $7.71B | Margin: 21.0% |
| #3 | BIOGEN INC.BIIB | $1.29B | Margin: 13.1% |
| #4 | EXELIXIS, INC.EXEL | $782.6M | Margin: 33.7% |
| #5 | NEUROCRINE BIOSCIENCES INCNBIX | $478.6M | Margin: 16.7% |
| #6 | NOVAVAX INCNVAX | $440.3M | Margin: 39.2% |
| #7 | HALOZYME THERAPEUTICS, INC.HALO | $316.9M | Margin: 22.7% |
| #8 | BIOCRYST PHARMACEUTICALS INCBCRX | $263.9M | Margin: 30.2% |
| #9 | Coherus Oncology, Inc.CHRS | $168.0M | Margin: 452.9% |
| #10 | ADMA BIOLOGICS, INC.ADMA | $146.9M | Margin: 28.8% |
| #11 | ELUTIA INC.ELUT | $53.4M | Margin: 434.2% |
| #12 | REPLIGEN CORPRGEN | $48.9M | Margin: 6.6% |
| #13 | Atara Biotherapeutics, Inc.ATRA | $32.7M | Margin: 27.1% |
| #14 | Vaxart, Inc.VXRT | $16.3M | Margin: 221.3% |
| #15 | SAB Biotherapeutics, Inc.SABS | $13.3M | — |
| #16 | CHAMPIONS ONCOLOGY, INC.CSBR | $4.7M | Margin: 8.3% |
| #17 | Abpro Holdings, Inc.ABPO | $2.8M | Margin: 1541.8% |